title: Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity.
abstract: BACKGROUND
  Measles control may be more challenging in regions with a high prevalence of HIV infection. HIV-infected children are likely to derive particular benefit from measles vaccines because of an increased risk of severe illness. However, HIV infection can impair vaccine effectiveness and may increase the risk of serious adverse events after receipt of live vaccines. We conducted a systematic review to assess the safety and immunogenicity of measles vaccine in HIV-infected children.
  
  
  METHODS
  The authors searched 8 databases through 12 February 2009 and reference lists. Study selection and data extraction were conducted in duplicate. Meta-analysis was conducted when appropriate.
  
  
  RESULTS
  Thirty-nine studies published from 1987 through 2008 were included. In 19 studies with information about measles vaccine safety, more than half reported no serious adverse events. Among HIV-infected children, 59% (95% confidence intervals [CI], 46-71%) were seropositive after receiving standard-titer measles vaccine at 6 months (1 study), comparable to the proportion of seropositive HIV-infected children vaccinated at 9 (8 studies) and 12 months (10 studies). Among HIV-exposed but uninfected and HIV-unexposed children, the proportion of seropositive children increased with increasing age at vaccination. Fewer HIV-infected children were protected after vaccination at 12 months than HIV-exposed but uninfected children (relative risk, 0.61; 95% CI, .50-.73).
  
  
  CONCLUSIONS
  Measles vaccines appear to be safe in HIV-infected children, but the evidence is limited. When the burden of measles is high, measles vaccination at 6 months of age is likely to benefit children of HIV-infected women, regardless of the child's HIV infection status.
authors.affiliation: Division of Clinical Epidemiology and Biostatistics, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, Bern, CH-3012, Switzerland.
authors.forename: Pippa
authors.initials: P
authors.lastname: Scott
authors.forename: William J
authors.initials: WJ
authors.lastname: Moss
authors.forename: Zunera
authors.initials: Z
authors.lastname: Gilani
authors.forename: Nicola
authors.initials: N
authors.lastname: Low
mesh_terms: D002648:Child; D015658:HIV Infections / Q000150:complications* / Q000276:immunology*; D006801:Humans; D008457:Measles / Q000150:complications* / Q000517:prevention & control*; D008458:Measles Vaccine / Q000009:adverse effects* / Q000276:immunology; D014611:Vaccination / Q000009:adverse effects*
chemical_list: D008458:Measles Vaccine